Paper: Solution-based pressurized metered dose inhaler formulations using HFA134a, HFA152a and HFO1234ze(E) propellants: Analysis of size, aerosolization performance and particle morphology
Dr Nirmal Marasini graduated with a PhD degree from the University of Queensland, Australia in 2017. He is currently a post-doctoral research fellow (June 2021-present) at the Respiratory technology group at Woolcock Institute of Medical Research, Sydney, Australia. Currently, Dr Marasini is working on research projects that incorporate formulations and characterisation of inhalable dry powders for simultaneous delivery of antibiotics and anti-inflammatory drugs and the development of pressurised metered dose inhalers (pMDIs) using a new generation of greener propellants HFA 152a and HFO 1234ze(E).
He has a research interest in the development of drug and vaccine delivery platforms or formulations against pulmonary diseases using novel nano/microtechnological approaches. His expertise broadly includes synthetic chemistry (drugs, lipids, peptides, and polymers), development of inhalable or nasal formulations, analysis of pharmaceutical compounds, in vitro biochemical analysis and in vivo animal pharmacokinetics and immunological studies.
Dr Marasini has published over 44 peer-reviewed research and review papers that have attracted over 1500 citations with an H-index of 25. He is an aspiring early career researcher and maintains active research collaboration within academia and activities in scientific societies. He is an expert reviewer or editor in more than 20 top scientific journals in the field of pharmacy, pharmaceutical science, biomaterials, and nanotechnologies.